Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
about
Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issuesThe role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision makingDo Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling?Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Estimating the Effect of Targeted Screening Strategies: An Application to Colonoscopy and Colorectal Cancer.Constructing Hypothetical Risk Data from the Area under the ROC Curve: Modelling Distributions of Polygenic Risk.Hereditary breast cancer: ever more pieces to the polygenic puzzle.Genetic control of ductal morphology, estrogen-induced ductal growth, and gene expression in female mouse mammary gland.Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium.Characterization of SNPs associated with prostate cancer in men of Ashkenazic descent from the set of GWAS identified SNPs: impact of cancer family history and cumulative SNP risk predictionPublic health genomics and personalized prevention: lessons from the COGS project.An epidemiological perspective of personalized medicine: the Estonian experience.A genome-wide pleiotropy scan for prostate cancer risk.Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK.Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.Can the breast screening appointment be used to provide risk assessment and prevention advice?Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3)Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma.End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine.Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women.Genetic architecture of colorectal cancer.Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers.Targeted Cancer Screening in Average-Risk Individuals.Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.Population-based screening in the era of genomicsTwenty-five years of breast cancer risk models and their applicationsReducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC.Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy.Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurementBreast cancer risk prediction and mammography biopsy decisions: a model-based study.Prediction of breast cancer risk based on profiling with common genetic variantsIntegration of genetic and epigenetic markers for risk stratification: opportunities and challenges.Molecular genetics of breast and ovarian cancer: recent advances and clinical implicationsPrediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status.Personalized screening for cancers: should we consider polygenic profiling?Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors.Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.
P2860
Q26825771-135446D3-550A-42D3-9C1C-58AA3ACA4164Q27025062-B9015D92-4BA0-4B82-87B9-1A029D39EB4BQ28084601-669BB561-E336-4CE6-AFE5-FD65F228FC4DQ30238753-292590D1-4304-4087-AE19-76867E8D9780Q30374367-2A5AB3C8-339B-434D-ACFE-F8A2E7D17864Q30854346-8C115914-0846-4726-9D5F-6D52FEE75724Q31064480-65FE9744-6EB6-4C04-BCFB-25A9D8434D31Q33356511-BBB0FA04-DBEA-4921-AFD8-9F0129E5E8F0Q33901182-B37D43C8-71EC-499C-BC7B-7644B0EE70CEQ34472668-0B101B89-EE5D-45BC-B70D-9E57153F0A4AQ34661857-97F28D5E-C0AA-4111-9909-1E720FAAAD96Q34811135-95A201B2-E33E-4F16-9A2C-CF49DFDECC8EQ35086233-DE8B814A-3744-483F-9117-ADC5358A5922Q35177444-5BC46729-4FB5-4EDB-9134-0E0CAE5C561BQ35592936-7F914FAC-AB75-4026-81F3-2F7444DFF7F8Q35602297-0D195333-95C6-41BE-834A-D30300AC2260Q35815958-FBC1EB11-A8E4-46CC-A627-88317AEF6C23Q35834376-6D19E51E-B97F-4138-A7B8-26EC4DE7FD06Q35868793-87FBCE8B-2F70-49F1-A685-3B2243C81423Q35885086-86B216D1-8C7E-4883-A045-99890C48013DQ35917987-2F491E73-2F73-4010-96D4-C071F2BA9D25Q35922603-565D107B-69CD-454F-A47A-1E12A5F16A32Q36053127-DD722F2B-2238-47D7-A933-B037E99601E7Q36097440-397B1A2F-74B0-4AF3-862C-695B72632AADQ36190584-2951EAF5-BB34-43E7-A9EF-CB1BCEA03EFDQ36229139-BC6D5205-3439-4722-80F5-7166DEEAB87FQ36233914-F880EB2F-BFE1-4685-B6A9-EA919ACF8752Q36294980-BA2235D6-2812-46CA-A0F6-31A893EBD461Q36295073-8A11B310-4EBE-4987-97DF-D64EBCFD0FECQ36356727-73118CC0-1DB0-4D95-A7BA-CC383FB9DCB9Q36387040-B0F6982F-9BEB-456D-8282-79FAE7C8C248Q36393193-1C298A9B-FC19-4ED1-B0DF-431E03B534AEQ36481548-9E7F472A-91D7-4817-B073-99BAE969B1ABQ36583004-3961FF9E-1412-43DF-9A54-2CDC9E350577Q36763159-A9CF028D-E518-4268-9490-ABBB3F5F6E01Q37181547-849FB4AB-0817-44EA-A0C9-4CB91758FFF2Q37223335-FDBAF8DA-5BB8-4F3B-A21D-1FF3E4987AC6Q37333975-58E1A9EE-2764-4ADF-ABFE-2E2FFE60935AQ37463923-2D59E508-EF68-44BD-835F-DE0FDC0429C2Q37513339-BB3C8FF0-81F2-42E3-A785-00ECFE39ED04
P2860
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Polygenic susceptibility to pr ...... ons for personalised screening
@ast
Polygenic susceptibility to pr ...... ons for personalised screening
@en
Polygenic susceptibility to pr ...... ons for personalised screening
@nl
type
label
Polygenic susceptibility to pr ...... ons for personalised screening
@ast
Polygenic susceptibility to pr ...... ons for personalised screening
@en
Polygenic susceptibility to pr ...... ons for personalised screening
@nl
prefLabel
Polygenic susceptibility to pr ...... ons for personalised screening
@ast
Polygenic susceptibility to pr ...... ons for personalised screening
@en
Polygenic susceptibility to pr ...... ons for personalised screening
@nl
P2093
P2860
P50
P356
P1476
Polygenic susceptibility to pr ...... ons for personalised screening
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2011.118
P407
P577
2011-04-05T00:00:00Z
P5875
P6179
1026293422